Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Arrowhead Pharmaceuticals. The associated price target remains the same with $80.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Arrowhead Pharmaceuticals’ strong position in the market. The recent FDA approval of REDEMPLO (plozasiran) as the first siRNA therapy for familial chylomicronemia syndrome (FCS) is a significant milestone. This approval is notable for its best-in-class profile, including quarterly at-home dosing, no contraindications, and applicability to both genetically confirmed and clinically diagnosed FCS patients. The Phase 3 trial results demonstrated an unprecedented median triglyceride reduction of approximately 80%, with a clean safety profile, which further strengthens its market potential.
Additionally, the strategic launch preparations and payer interactions covering a substantial portion of U.S. lives position REDEMPLO as a foundational product in the rare-disease market. The One-REDEMPLO pricing strategy is expected to anchor long-term value, particularly in the high-risk severe hypertriglyceridemia (sHTG) segment. With upcoming Phase 3 trial data expected in the third quarter of 2026, Arrowhead Pharmaceuticals is well-positioned for a multi-year expansion cycle, further justifying the Buy rating and the $80 price target.